"Breakout Ventures describes Fund III as AI-focused, which in 2026 is not exactly a differentiating claim. What it means in practice is narrower and more interesting: the firm believes that the most valuable AI opportunities in biology are not chatbots or administrative tools but systems that can genuinely accelerate how science turns into medicine. Drug discovery. Diagnostics. Neurotechnology. Materials."
"Lindy Fishburne started Breakout in a somewhat unusual place: inside the Thiel Foundation, running a grant programme called Breakout Labs that handed speculative cheques to scientist-entrepreneurs working on problems too radical for traditional venture capital and too commercially oriented for academic funding. That was 2011."
Breakout Ventures, founded by Lindy Fishburne from the Thiel Foundation's Breakout Labs grant program, has closed its third fund at $114 million, bringing total assets under management to over $230 million. The firm evolved from distributing grants to scientist-entrepreneurs in 2011 to launching venture funds in 2017 and 2021. Fund III targets the convergence of AI and biology, specifically focusing on applications that accelerate scientific advancement into medicine, including drug discovery, diagnostics, neurotechnology, and materials science. The expanded team includes founders and scientists as partners, emphasizing the transition from scientific expertise to entrepreneurship. The portfolio demonstrates the firm's commitment to companies operating at the intersection of computation and laboratory research.
Read at TNW | Investors-Funding
Unable to calculate read time
Collection
[
|
...
]